GSK won FDA approval for Jideytro (zidesamtinib), its ROS1 inhibitor for ROS1-positive non-small cell lung cancer, ahead of the September 18 deadline as part of its Nuvalent acquisition. The treatment, showing a 44% response rate in trials, positions GSK to compete in lung cancer and supports ongoing development of additional Nuvalent assets like neladalkib and ris-rez.

Health· Jul 23, 2026

Facts from Wikidata (CC0).

entrectinib

composto químico

3membros1here now

Pergunte ao Genius Site

Site Jornal

Feed Discussões Sobre

Sort by

Content type

Últimas notícias e discussão sobre entrectinib

Sort by

Content type

Eentrectinib· Health · 9 sources · Jul 23, 2026Story

GSK earns FDA approval for Jideytro

Health· Jul 23, 2026

Facts from Wikidata (CC0).

entrectinib across IJR

Ask Genius by OpenServe about entrectinib Create in Studio Build a game Watch videos

About entrectinib

Entrectinib, vendido sob o nome comercial Rozlytrek, é um medicamento anticâncer usado para tratar câncer de pulmão de células não pequenas positivo para ROS1 e tumores sólidos positivos para fusão de NTRK. É um inibidor seletivo de tirosina quinase (TKI), das quinases receptoras de tropomiosina (TRK) A, B e C, oncogene C-ros 1 (ROS1) e quinase do linfoma anaplásico (ALK).

members

here now

Coverage spread L0 / C75 / R25

Everything about entrectinib →

Live room · 1 here

Be the first in the room — members see you arrive.

Join the room

entrectinib across IJR

Ask Genius by OpenServe about entrectinib Create in Studio Build a game Watch videos